Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.07 USD | +0.98% | +2.16% | +17.61% |
Mar. 14 | Top Premarket Gainers | MT |
Mar. 13 | Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 46.7 | 12.18 | 14.79 | 17.68 | - | - |
Enterprise Value (EV) 1 | 46.7 | 12.18 | 14.79 | 17.68 | 17.68 | 17.68 |
P/E ratio | -3.02 x | -0.84 x | -0.96 x | -1.04 x | -1.45 x | -1.63 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 8,194 | 8,401 | 8,401 | 8,539 | - | - |
Reference price 2 | 5.700 | 1.450 | 1.760 | 2.070 | 2.070 | 2.070 |
Announcement Date | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - |
EBIT 1 | - | -7.729 | -14.91 | -16.38 | -21.17 | -23.98 | -22.81 |
Operating Margin | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -7.711 | -14.32 | -15.42 | -21.17 | -23.68 | -22.81 |
Net income 1 | -3.584 | -7.711 | -14.32 | -15.42 | -21.17 | -23.68 | -22.81 |
Net margin | - | - | - | - | - | - | - |
EPS 2 | -4.890 | -1.890 | -1.730 | -1.830 | -1.995 | -1.425 | -1.270 |
Free Cash Flow | - | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 4/20/21 | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -3.368 | -3.218 | -3.402 | -3.869 | -3.553 | -4.087 | -4.455 | -3.495 | -4.248 | -4.18 | -3.943 | -4.732 | -5.678 | -6.814 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -3.367 | -3.216 | -3.365 | -3.836 | -3.466 | -3.656 | -4.253 | -3.245 | -3.922 | -4.003 | -3.807 | -4.732 | -5.678 | -6.814 |
Net income 1 | -3.367 | -3.216 | -3.365 | -3.836 | -3.466 | -3.656 | -4.253 | -3.245 | -3.922 | -4.003 | -3.807 | -4.732 | -5.678 | -6.814 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.8100 | -0.2200 | -0.4100 | -0.4600 | -0.4200 | -0.4400 | -0.5100 | -0.3900 | -0.4700 | -0.4700 | -0.4500 | -0.6000 | -0.4200 | -0.3400 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/21/22 | 5/12/22 | 8/8/22 | 11/10/22 | 3/17/23 | 5/11/23 | 8/14/23 | 11/6/23 | 3/13/24 | 5/8/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex | - | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - | - |
Announcement Date | 4/20/21 | 3/21/22 | 3/17/23 | 3/13/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.61% | 17.5M | |
+22.56% | 46.4B | |
-1.51% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.13% | 26.01B | |
-20.44% | 19.52B | |
+26.45% | 12.43B | |
-0.14% | 12.18B | |
-0.47% | 12.13B |
- Stock Market
- Equities
- INDP Stock
- Financials Indaptus Therapeutics, Inc.